Carmed Pharmaceuticals Gains CityBiz Feature as U.S. Expansion Accelerates
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol-based formulations, is highlighted in a CityBiz Q&A with founder Mustafa Can as it expands into the U.S. market through platforms like OneLavi and Amazon.
Carmed Pharmaceuticals, a Turkey-based science-driven company specializing in standardized carvacrol-based formulations, has earned editorial coverage in CityBiz through a featured executive Q&A with founder Mustafa Can as the company continues its expansion into the United States market. The interview explores Can's unconventional journey from ship master to founder of a research-focused pharmaceutical company and discusses Carmed's formulation philosophy, ongoing research, and strategy for entering the U.S. wellness market.
In the interview, Can explains how a personal interest in longevity and preventive wellness led him into years of independent research before formally establishing Carmed Pharmaceuticals. "Over time, this personal journey evolved into something more structured," Can said. "I became increasingly focused on how to develop standardized, reproducible formulations based on bioactive compounds like carvacrol." The article highlights Carmed's emphasis on "rational synergy," combining multiple bioactive compounds within standardized formulations designed for consistency, reproducibility, and analytical validation.
The CityBiz placement comes as Carmed builds awareness in the United States through a multi-channel distribution strategy that includes curated wellness platforms and large-scale digital marketplaces. Several Carmed formulations are now available on OneLavi.com, including Vacrol® Kids Spray, S-Mix®, Vacrol® Capsule, and Vacrol-M® Capsule. Vacrol® Kids Spray and S-Mix® are gluten-free, non-GMO, sugar-free, preservative-free, and halal-certified. The company has also announced plans to expand availability through Amazon as part of its broader U.S. rollout strategy.
"We believe educational visibility and accessibility must develop together," said Ceren Can, Global Brand Director of Carmed Pharmaceuticals. "The CityBiz feature helps communicate the philosophy behind Carmed while platforms like OneLavi and Amazon help make our formulations more accessible to consumers in the United States."
The CityBiz interview also discusses Carmed's commitment to scientific collaboration and ongoing research. In January 2026, research involving Carmed formulations Vacrol® and S-Mix® was published in the peer-reviewed journal Plants, where the formulations were examined in preclinical models as part of broader scientific investigation into carvacrol-based botanical formulations. The company emphasizes that this research reflects scientific investigation into formulation science and botanical bioactivity and is not presented as evidence that its consumer products diagnose, treat, cure, or prevent any disease.
Carmed states that its U.S. strategy is focused on long-term brand development through scientific credibility, regulatory alignment, educational visibility, and expanded consumer accessibility. "Our goal is to build a company that is known for consistency, credibility, and a long-term commitment to research-driven development," Can said in the CityBiz feature. The full CityBiz Q&A with Mustafa Can can be viewed here.